Matches in SemOpenAlex for { <https://semopenalex.org/work/W3109853980> ?p ?o ?g. }
- W3109853980 endingPage "1828" @default.
- W3109853980 startingPage "1817" @default.
- W3109853980 abstract "Background Pembrolizumab monotherapy showed durable antitumour activity and manageable safety in patients with metastatic triple-negative breast cancer. We aimed to examine whether the addition of pembrolizumab would enhance the antitumour activity of chemotherapy in patients with metastatic triple-negative breast cancer. Methods In this randomised, placebo-controlled, double-blind, phase 3 trial, done in 209 sites in 29 countries, we randomly assigned patients 2:1 with untreated locally recurrent inoperable or metastatic triple-negative breast cancer using a block method (block size of six) and an interactive voice-response system with integrated web-response to pembrolizumab (200 mg) every 3 weeks plus chemotherapy (nab-paclitaxel; paclitaxel; or gemcitabine plus carboplatin) or placebo plus chemotherapy. Randomisation was stratified by type of on-study chemotherapy (taxane or gemcitabine–carboplatin), PD-L1 expression at baseline (combined positive score [CPS] ≥1 or <1), and previous treatment with the same class of chemotherapy in the neoadjuvant or adjuvant setting (yes or no). Eligibility criteria included age at least 18 years, centrally confirmed triple-negative breast cancer; at least one measurable lesion; provision of a newly obtained tumour sample for determination of triple-negative breast cancer status and PD-L1 status by immunohistochemistry at a central laboratory; an Eastern Cooperative Oncology Group performance status score 0 or 1; and adequate organ function. The sponsor, investigators, other study site staff (except for the unmasked pharmacist), and patients were masked to pembrolizumab versus saline placebo administration. In addition, the sponsor, the investigators, other study site staff, and patients were masked to patient-level tumour PD-L1 biomarker results. Dual primary efficacy endpoints were progression-free survival and overall survival assessed in the PD-L1 CPS of 10 or more, CPS of 1 or more, and intention-to-treat populations. The definitive assessment of progression-free survival was done at this interim analysis; follow-up to assess overall survival is continuing. For progression-free survival, a hierarchical testing strategy was used, such that testing was done first in patients with CPS of 10 or more (prespecified statistical criterion was α=0·00411 at this interim analysis), then in patients with CPS of 1 or more (α=0·00111 at this interim analysis, with partial alpha from progression-free survival in patients with CPS of 10 or more passed over), and finally in the intention-to-treat population (α=0·00111 at this interim analysis). This study is registered with ClinicalTrials.gov, NCT02819518, and is ongoing. Findings Between Jan 9, 2017, and June 12, 2018, of 1372 patients screened, 847 were randomly assigned to treatment, with 566 patients in the pembrolizumab–chemotherapy group and 281 patients in the placebo–chemotherapy group. At the second interim analysis (data cutoff, Dec 11, 2019), median follow-up was 25·9 months (IQR 22·8–29·9) in the pembrolizumab–chemotherapy group and 26·3 months (22·7–29·7) in the placebo–chemotherapy group. Among patients with CPS of 10 or more, median progression-free survival was 9·7 months with pembrolizumab–chemotherapy and 5·6 months with placebo–chemotherapy (hazard ratio [HR] for progression or death, 0·65, 95% CI 0·49–0·86; one-sided p=0·0012 [primary objective met]). Median progression-free survival was 7·6 and 5·6 months (HR, 0·74, 0·61–0·90; one-sided p=0·0014 [not significant]) among patients with CPS of 1 or more and 7·5 and 5·6 months (HR, 0·82, 0·69–0·97 [not tested]) among the intention-to-treat population. The pembrolizumab treatment effect increased with PD-L1 enrichment. Grade 3–5 treatment-related adverse event rates were 68% in the pembrolizumab–chemotherapy group and 67% in the placebo–chemotherapy group, including death in <1% in the pembrolizumab–chemotherapy group and 0% in the placebo–chemotherapy group. Interpretation Pembrolizumab–chemotherapy showed a significant and clinically meaningful improvement in progression-free survival versus placebo–chemotherapy among patients with metastatic triple-negative breast cancer with CPS of 10 or more. These findings suggest a role for the addition of pembrolizumab to standard chemotherapy for the first-line treatment of metastatic triple-negative breast cancer. Funding Merck Sharp & Dohme Corp, a subsidiary of Merck & Co, Inc. Pembrolizumab monotherapy showed durable antitumour activity and manageable safety in patients with metastatic triple-negative breast cancer. We aimed to examine whether the addition of pembrolizumab would enhance the antitumour activity of chemotherapy in patients with metastatic triple-negative breast cancer. In this randomised, placebo-controlled, double-blind, phase 3 trial, done in 209 sites in 29 countries, we randomly assigned patients 2:1 with untreated locally recurrent inoperable or metastatic triple-negative breast cancer using a block method (block size of six) and an interactive voice-response system with integrated web-response to pembrolizumab (200 mg) every 3 weeks plus chemotherapy (nab-paclitaxel; paclitaxel; or gemcitabine plus carboplatin) or placebo plus chemotherapy. Randomisation was stratified by type of on-study chemotherapy (taxane or gemcitabine–carboplatin), PD-L1 expression at baseline (combined positive score [CPS] ≥1 or <1), and previous treatment with the same class of chemotherapy in the neoadjuvant or adjuvant setting (yes or no). Eligibility criteria included age at least 18 years, centrally confirmed triple-negative breast cancer; at least one measurable lesion; provision of a newly obtained tumour sample for determination of triple-negative breast cancer status and PD-L1 status by immunohistochemistry at a central laboratory; an Eastern Cooperative Oncology Group performance status score 0 or 1; and adequate organ function. The sponsor, investigators, other study site staff (except for the unmasked pharmacist), and patients were masked to pembrolizumab versus saline placebo administration. In addition, the sponsor, the investigators, other study site staff, and patients were masked to patient-level tumour PD-L1 biomarker results. Dual primary efficacy endpoints were progression-free survival and overall survival assessed in the PD-L1 CPS of 10 or more, CPS of 1 or more, and intention-to-treat populations. The definitive assessment of progression-free survival was done at this interim analysis; follow-up to assess overall survival is continuing. For progression-free survival, a hierarchical testing strategy was used, such that testing was done first in patients with CPS of 10 or more (prespecified statistical criterion was α=0·00411 at this interim analysis), then in patients with CPS of 1 or more (α=0·00111 at this interim analysis, with partial alpha from progression-free survival in patients with CPS of 10 or more passed over), and finally in the intention-to-treat population (α=0·00111 at this interim analysis). This study is registered with ClinicalTrials.gov, NCT02819518, and is ongoing. Between Jan 9, 2017, and June 12, 2018, of 1372 patients screened, 847 were randomly assigned to treatment, with 566 patients in the pembrolizumab–chemotherapy group and 281 patients in the placebo–chemotherapy group. At the second interim analysis (data cutoff, Dec 11, 2019), median follow-up was 25·9 months (IQR 22·8–29·9) in the pembrolizumab–chemotherapy group and 26·3 months (22·7–29·7) in the placebo–chemotherapy group. Among patients with CPS of 10 or more, median progression-free survival was 9·7 months with pembrolizumab–chemotherapy and 5·6 months with placebo–chemotherapy (hazard ratio [HR] for progression or death, 0·65, 95% CI 0·49–0·86; one-sided p=0·0012 [primary objective met]). Median progression-free survival was 7·6 and 5·6 months (HR, 0·74, 0·61–0·90; one-sided p=0·0014 [not significant]) among patients with CPS of 1 or more and 7·5 and 5·6 months (HR, 0·82, 0·69–0·97 [not tested]) among the intention-to-treat population. The pembrolizumab treatment effect increased with PD-L1 enrichment. Grade 3–5 treatment-related adverse event rates were 68% in the pembrolizumab–chemotherapy group and 67% in the placebo–chemotherapy group, including death in <1% in the pembrolizumab–chemotherapy group and 0% in the placebo–chemotherapy group. Pembrolizumab–chemotherapy showed a significant and clinically meaningful improvement in progression-free survival versus placebo–chemotherapy among patients with metastatic triple-negative breast cancer with CPS of 10 or more. These findings suggest a role for the addition of pembrolizumab to standard chemotherapy for the first-line treatment of metastatic triple-negative breast cancer." @default.
- W3109853980 created "2020-12-07" @default.
- W3109853980 creator A5000647160 @default.
- W3109853980 creator A5001470219 @default.
- W3109853980 creator A5001602150 @default.
- W3109853980 creator A5001764588 @default.
- W3109853980 creator A5002704393 @default.
- W3109853980 creator A5002930409 @default.
- W3109853980 creator A5003395286 @default.
- W3109853980 creator A5003433691 @default.
- W3109853980 creator A5004131258 @default.
- W3109853980 creator A5004315779 @default.
- W3109853980 creator A5004382357 @default.
- W3109853980 creator A5004644866 @default.
- W3109853980 creator A5004668866 @default.
- W3109853980 creator A5005552319 @default.
- W3109853980 creator A5005649210 @default.
- W3109853980 creator A5005957279 @default.
- W3109853980 creator A5006432650 @default.
- W3109853980 creator A5006496284 @default.
- W3109853980 creator A5006565048 @default.
- W3109853980 creator A5007053770 @default.
- W3109853980 creator A5008048264 @default.
- W3109853980 creator A5008166009 @default.
- W3109853980 creator A5008356782 @default.
- W3109853980 creator A5008427928 @default.
- W3109853980 creator A5008455014 @default.
- W3109853980 creator A5008549101 @default.
- W3109853980 creator A5008946028 @default.
- W3109853980 creator A5009247132 @default.
- W3109853980 creator A5009341892 @default.
- W3109853980 creator A5009523282 @default.
- W3109853980 creator A5009947400 @default.
- W3109853980 creator A5010028400 @default.
- W3109853980 creator A5010278367 @default.
- W3109853980 creator A5010438940 @default.
- W3109853980 creator A5010745978 @default.
- W3109853980 creator A5011022075 @default.
- W3109853980 creator A5011523057 @default.
- W3109853980 creator A5013064031 @default.
- W3109853980 creator A5013080783 @default.
- W3109853980 creator A5013265515 @default.
- W3109853980 creator A5013493137 @default.
- W3109853980 creator A5013823331 @default.
- W3109853980 creator A5014613098 @default.
- W3109853980 creator A5015450747 @default.
- W3109853980 creator A5016824553 @default.
- W3109853980 creator A5017065625 @default.
- W3109853980 creator A5017407318 @default.
- W3109853980 creator A5018682015 @default.
- W3109853980 creator A5018846439 @default.
- W3109853980 creator A5019124736 @default.
- W3109853980 creator A5019700918 @default.
- W3109853980 creator A5019920360 @default.
- W3109853980 creator A5019922047 @default.
- W3109853980 creator A5021782707 @default.
- W3109853980 creator A5022232240 @default.
- W3109853980 creator A5022641576 @default.
- W3109853980 creator A5023874099 @default.
- W3109853980 creator A5025461663 @default.
- W3109853980 creator A5026210554 @default.
- W3109853980 creator A5026239316 @default.
- W3109853980 creator A5027231412 @default.
- W3109853980 creator A5027877389 @default.
- W3109853980 creator A5027981189 @default.
- W3109853980 creator A5028002409 @default.
- W3109853980 creator A5028569350 @default.
- W3109853980 creator A5029173659 @default.
- W3109853980 creator A5029247118 @default.
- W3109853980 creator A5030366726 @default.
- W3109853980 creator A5031064876 @default.
- W3109853980 creator A5031649390 @default.
- W3109853980 creator A5031944340 @default.
- W3109853980 creator A5032414477 @default.
- W3109853980 creator A5032446221 @default.
- W3109853980 creator A5033494478 @default.
- W3109853980 creator A5033662772 @default.
- W3109853980 creator A5033782859 @default.
- W3109853980 creator A5034804495 @default.
- W3109853980 creator A5035336917 @default.
- W3109853980 creator A5035354858 @default.
- W3109853980 creator A5035439475 @default.
- W3109853980 creator A5035784421 @default.
- W3109853980 creator A5036135239 @default.
- W3109853980 creator A5036348595 @default.
- W3109853980 creator A5036629754 @default.
- W3109853980 creator A5037588013 @default.
- W3109853980 creator A5037653968 @default.
- W3109853980 creator A5038885313 @default.
- W3109853980 creator A5039200681 @default.
- W3109853980 creator A5039764924 @default.
- W3109853980 creator A5040317104 @default.
- W3109853980 creator A5040423842 @default.
- W3109853980 creator A5041441650 @default.
- W3109853980 creator A5041750568 @default.
- W3109853980 creator A5042295867 @default.
- W3109853980 creator A5042433886 @default.
- W3109853980 creator A5043515426 @default.